AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Investment analysts at Piper Jaffray Companies issued their Q1 2020 earnings per share (EPS) estimates for shares of AMAG Pharmaceuticals in a research report issued on Thursday, February 7th. Piper Jaffray Companies analyst C. Raymond anticipates that the specialty pharmaceutical company will earn ($0.68) per share for the quarter. Piper Jaffray Companies also issued estimates for AMAG Pharmaceuticals’ Q2 2020 earnings at ($0.74) EPS, Q3 2020 earnings at ($0.77) EPS and Q4 2020 earnings at ($0.74) EPS.
Get AMAG Pharmaceuticals alerts:AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.38. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. The business had revenue of $88.10 million for the quarter, compared to analyst estimates of $95.21 million. During the same period in the previous year, the business earned $0.10 EPS. The firm’s revenue was down 31.4% on a year-over-year basis.
AMAG has been the topic of a number of other reports. B. Riley restated a “buy” rating and issued a $20.50 price target (down from $29.00) on shares of AMAG Pharmaceuticals in a research report on Friday, December 14th. Cantor Fitzgerald set a $18.00 price target on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research report on Friday, November 2nd. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Finally, JPMorgan Chase & Co. lowered shares of AMAG Pharmaceuticals from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $20.00 to $18.00 in a research report on Tuesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. AMAG Pharmaceuticals has an average rating of “Hold” and a consensus target price of $20.97.
Shares of AMAG Pharmaceuticals stock opened at $15.19 on Friday. The stock has a market cap of $524.66 million, a PE ratio of -3.91 and a beta of 0.45. AMAG Pharmaceuticals has a twelve month low of $11.95 and a twelve month high of $26.10. The company has a current ratio of 3.17, a quick ratio of 2.72 and a debt-to-equity ratio of 0.35.
Large investors have recently added to or reduced their stakes in the business. AXA boosted its position in AMAG Pharmaceuticals by 217.3% in the third quarter. AXA now owns 93,600 shares of the specialty pharmaceutical company’s stock valued at $1,872,000 after buying an additional 64,100 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of AMAG Pharmaceuticals by 369.6% during the third quarter. Pacer Advisors Inc. now owns 17,364 shares of the specialty pharmaceutical company’s stock worth $347,000 after purchasing an additional 13,666 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of AMAG Pharmaceuticals by 2.2% during the third quarter. Vanguard Group Inc. now owns 3,281,854 shares of the specialty pharmaceutical company’s stock worth $65,638,000 after purchasing an additional 69,550 shares in the last quarter. Vanguard Group Inc lifted its position in shares of AMAG Pharmaceuticals by 2.2% during the third quarter. Vanguard Group Inc now owns 3,281,854 shares of the specialty pharmaceutical company’s stock worth $65,638,000 after purchasing an additional 69,550 shares in the last quarter. Finally, Federated Investors Inc. PA lifted its position in shares of AMAG Pharmaceuticals by 62.8% during the third quarter. Federated Investors Inc. PA now owns 132,579 shares of the specialty pharmaceutical company’s stock worth $2,652,000 after purchasing an additional 51,137 shares in the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Further Reading: What is the Dow Jones Industrial Average (DJIA)?
No comments:
Post a Comment